202 related articles for article (PubMed ID: 35439028)
1. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK; Claes K; Goh YT; Kwong YL; Leung N; Mendrek W; Nakamura R; Sathar J; Ng E; Nangia N; Whitaker S; Rambaldi A;
J Clin Oncol; 2022 Aug; 40(22):2447-2457. PubMed ID: 35439028
[TBL] [Abstract][Full Text] [Related]
2. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
3. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
Elhadad S; Redmond D; Huang J; Tan A; Laurence J
Clin Exp Immunol; 2023 Jul; 213(2):252-264. PubMed ID: 37191586
[TBL] [Abstract][Full Text] [Related]
4. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.
Castelli M; Micò MC; Grassi A; Algarotti A; Lussana F; Finazzi MC; Rambaldi B; Pavoni C; Rizzuto G; Tebaldi P; Vendemini F; Verna M; Bonanomi S; Biondi A; Balduzzi A; Rambaldi A; Gotti G
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38773280
[TBL] [Abstract][Full Text] [Related]
6. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
[TBL] [Abstract][Full Text] [Related]
7. Narsoplimab for severe transplant-associated thrombotic microangiopathy.
Pandrowala A; Ganatra P; Krishnan VP; Sharma AN; Chavan S; Bodhanwala M; Agarwal B; Hiwarkar P
Thromb J; 2023 Mar; 21(1):26. PubMed ID: 36915123
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.
Dudler T; Yaseen S; Cummings WJ
Front Immunol; 2023; 14():1297352. PubMed ID: 38022610
[TBL] [Abstract][Full Text] [Related]
9. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
10. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
12. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
Lazana I
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
15. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy.
Gavriilaki E; Ho VT; Schwaeble W; Dudler T; Daha M; Fujita T; Jodele S
Exp Hematol Oncol; 2021 Dec; 10(1):57. PubMed ID: 34924021
[TBL] [Abstract][Full Text] [Related]
16. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
17. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
19. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments.
Wanchoo R; Bayer RL; Bassil C; Jhaveri KD
Am J Kidney Dis; 2018 Dec; 72(6):857-865. PubMed ID: 30146419
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy.
Lafayette RA; Rovin BH; Reich HN; Tumlin JA; Floege J; Barratt J
Kidney Int Rep; 2020 Nov; 5(11):2032-2041. PubMed ID: 33163724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]